View Future GrowthAIxCrypto Holdings 過去の業績過去 基準チェック /06AIxCrypto Holdingsは14%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで29.1%毎年増加している。売上は減少しており、年平均68.3%の割合である。主要情報14.03%収益成長率55.99%EPS成長率Biotechs 業界の成長17.04%収益成長率-68.32%株主資本利益率-60.70%ネット・マージンn/a前回の決算情報31 Dec 2025最近の業績更新AIxCrypto Holdings, Inc. to Report Q4, 2025 Results on Mar 24, 2026Mar 21Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 16Full year 2022 earnings: EPS and revenues miss analyst expectations May 03Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 17Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Apr 02すべての更新を表示Recent updatesNew major risk - Share price stability Mar 23AIxCrypto Holdings, Inc. to Report Q4, 2025 Results on Mar 24, 2026Mar 21AIxC Hub Surpasses 4.8M Registered Wallets, Introduces New Season, and Announces "Agentir" for AI AgentsFeb 26New major risk - Market cap size Feb 06AIxCrypto Inc. Launches AIxC Hub Ecosystem PlatformJan 12Is AIxCrypto Holdings (NASDAQ:AIXC) Weighed On By Its Debt Load?Dec 30AIxCrypto Holdings, Inc., Annual General Meeting, Dec 30, 2025Dec 16AIxCrypto Inc. Appoints Andrew Grossman As Head Of Legal, Effective December 14, 2025Dec 15AIxCrypto Holdings, Inc. Receives Letter of Non-Compliance with Nasdaq Listing Rule 5635(b) and Compliance with Nasdaq Listing Rule 5550(b)(1)Nov 22Qualigen Therapeutics, Inc. Announces Board and Committee ChangesOct 07Qualigen Therapeutics, Inc. announced that it has received $41 million in funding from Faraday Future Intelligent Electric Inc., Sequoia Capital, IDgo, Inc., Circle Internet Group, Inc.Oct 01Qualigen Therapeutics, Inc. Appoints Jerry Wang as Co-CEOSep 30+ 1 more updateQualigen Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.Sep 25Qualigen Therapeutics, Inc. Announces Notice of Compliance Decision and Nasdaq Listing Status UpdateSep 09New minor risk - Share price stability Aug 31New major risk - Negative shareholders equity Aug 15Qualigen Therapeutics, Inc. Provides Update on Nasdaq Listing StatusJul 29+ 1 more updateHigh number of new and inexperienced directors Jul 01Qualigen Therapeutics Receives Nasdaq Deficiency Notification for Delayed FilingMay 20Qualigen Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-KMay 02Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered a non-binding Memorandum of Understanding to acquire Marizyme, Inc. (OTCPK:MRZM)Apr 02+ 1 more updateQualigen Therapeutics, Inc. announced that it has received $5.1 million in fundingNov 22Qualigen Therapeutics, Inc. announced that it expects to receive $4.5 million in fundingNov 20Qualigen Therapeutics to Implement a 1-for-50 Reverse Stock Split, to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital MarketNov 01Qualigen Therapeutics, Inc. has filed a Follow-on Equity Offering.Oct 25Qualigen Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Audit CommitteeOct 23Qualigen Therapeutics, Inc. Announces Board and Committee ChangesOct 10Qualigen Therapeutics, Inc. Announces Chief Financial Officer ChangesSep 27+ 2 more updatesNew major risk - Financial data availability Sep 16Less than half of directors are independent Aug 14The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity RuleAug 06Qualigen Therapeutics, Inc., Annual General Meeting, Sep 17, 2024Jul 17Qualigen Therapeutics, Inc. Announces Board ChangesJul 15Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)May 31Qualigen Therapeutics, Inc. announced delayed 10-Q filingMay 16Qualigen Therapeutics, Inc. announced delayed annual 10-K filingApr 02Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital AnstaltFeb 27Consensus revenue estimates decrease by 14%, EPS upgraded Nov 28Qualigen Therapeutics Receives a Letter from the Nasdaq Stock MarketNov 23Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNov 08Consensus EPS estimates fall by 57% Aug 31Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 16Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid TumorsAug 02Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).Jul 26New minor risk - Share price stability Jul 21Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and DirectorJun 29Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJun 06Qualigen Therapeutics, Inc., Annual General Meeting, Jul 13, 2023Jun 03Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023May 20Price target decreased by 23% to US$27.00 May 19Consensus revenue estimates decrease by 12% May 14Full year 2022 earnings: EPS and revenues miss analyst expectations May 03Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302Jan 25Qualigen Therapeutics, Inc. Announces Executive ChangesJan 22Consensus forecasts updated Nov 21High number of new and inexperienced directors Nov 16High number of new and inexperienced directors Sep 02Consensus forecasts updated Aug 26Consensus revenue estimates increase by 10% Aug 22Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 17Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302 Jul 06Price target decreased to US$5.75 Jul 05Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Apr 02Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?Mar 08We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn RateNov 23収支内訳AIxCrypto Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:AIXC 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 250-209030 Sep 250-87030 Jun 250-76031 Mar 250-76031 Dec 240-64130 Sep 240-84030 Jun 240-94031 Mar 240-116031 Dec 230-126030 Sep 230-148030 Jun 23-2-128031 Mar 23-1-139031 Dec 220-1410030 Sep 221-1511030 Jun 225-1612031 Mar 224-1712031 Dec 216-1812030 Sep 215-712030 Jun 215-1211031 Mar 215-2510031 Dec 204-208030 Sep 205-286030 Jun 205-204031 Mar 206-22031 Dec 195-11031 Mar 196-11031 Mar 1810020質の高い収益: AIXCは現在利益が出ていません。利益率の向上: AIXCは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: AIXCは利益を出していないが、過去 5 年間で年間14%の割合で損失を削減してきた。成長の加速: AIXCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: AIXCは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 50.1% ) と比較することは困難です。株主資本利益率高いROE: AIXCは現在利益が出ていないため、自己資本利益率 ( -60.7% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/04/30 04:52終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AIxCrypto Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関James MolloyAlliance Global PartnersDavid BautzZacks Small-Cap Research
AIxC Hub Surpasses 4.8M Registered Wallets, Introduces New Season, and Announces "Agentir" for AI AgentsFeb 26
AIxCrypto Holdings, Inc. Receives Letter of Non-Compliance with Nasdaq Listing Rule 5635(b) and Compliance with Nasdaq Listing Rule 5550(b)(1)Nov 22
Qualigen Therapeutics, Inc. announced that it has received $41 million in funding from Faraday Future Intelligent Electric Inc., Sequoia Capital, IDgo, Inc., Circle Internet Group, Inc.Oct 01
Qualigen Therapeutics, Inc. Announces Notice of Compliance Decision and Nasdaq Listing Status UpdateSep 09
Qualigen Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-KMay 02
Qualigen Therapeutics, Inc. (NasdaqCM:QLGN) entered a non-binding Memorandum of Understanding to acquire Marizyme, Inc. (OTCPK:MRZM)Apr 02+ 1 more update
Qualigen Therapeutics to Implement a 1-for-50 Reverse Stock Split, to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital MarketNov 01
The Nasdaq Hearings Panel Grants Qualigen Therapeutics Until October 31, 2024 to Regain Compliance with the Bid Price Rule and the Equity RuleAug 06
Qualigen Therapeutics Receives Nasdaq Notice of a Delisting Determination Due to its Continued Non-Compliance with the Minimum Bid Price Requirement, Pursuant to Listing Rule 5550(b)(2)May 31
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital AnstaltFeb 27
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNov 08
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid TumorsAug 02
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. (NasdaqCM:QLGN).Jul 26
Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and DirectorJun 29
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJun 06
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023May 20